相似文献
1
Editorial: Genetics and Molecular Mechanisms of Oral and Esophageal Squamous Cell Carcinoma.
Front Oncol. 2022 Apr 6;12:874353. doi: 10.3389/fonc.2022.874353. eCollection 2022.
2
Novel candidate genes may be possible predisposing factors revealed by whole exome sequencing in familial esophageal squamous cell carcinoma.
Tumour Biol. 2017 May;39(5):1010428317699115. doi: 10.1177/1010428317699115.
3
Genome Sequencing in Esophageal Squamous Cell Carcinoma.
Methods Mol Biol. 2020;2129:217-240. doi: 10.1007/978-1-0716-0377-2_17.
4
Genomic characterization of esophageal squamous cell carcinoma: Insights from next-generation sequencing.
World J Gastroenterol. 2016 Feb 21;22(7):2284-93. doi: 10.3748/wjg.v22.i7.2284.
5
Personalized targeted therapy for esophageal squamous cell carcinoma.
World J Gastroenterol. 2015 Jul 7;21(25):7648-58. doi: 10.3748/wjg.v21.i25.7648.
6
Genomic comparison of esophageal squamous cell carcinoma and its precursor lesions by multi-region whole-exome sequencing.
Nat Commun. 2017 Sep 12;8(1):524. doi: 10.1038/s41467-017-00650-0.
7
Genomic profiling of esophageal squamous cell carcinoma (ESCC)-Basis for precision medicine.
Pathol Res Pract. 2017 Jul;213(7):836-841. doi: 10.1016/j.prp.2017.02.021. Epub 2017 Feb 28.
8
Exome Sequencing of Oral Squamous Cell Carcinoma Reveals Molecular Subgroups and Novel Therapeutic Opportunities.
Theranostics. 2017 Feb 26;7(5):1088-1099. doi: 10.7150/thno.18551. eCollection 2017.
9
An Old Story Retold: Loss of G1 Control Defines A Distinct Genomic Subtype of Esophageal Squamous Cell Carcinoma.
Genomics Proteomics Bioinformatics. 2015 Aug;13(4):258-70. doi: 10.1016/j.gpb.2015.06.003. Epub 2015 Sep 16.
10
Toward the use of precision medicine for the treatment of head and neck squamous cell carcinoma.
Oncotarget. 2017 Jan 10;8(2):2141-2152. doi: 10.18632/oncotarget.13798.
本文引用的文献
1
Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment.
J Pers Med. 2021 May 10;11(5):393. doi: 10.3390/jpm11050393.
2
Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.
Nat Commun. 2021 Apr 22;12(1):2383. doi: 10.1038/s41467-021-22619-w.
3
Head and Neck Cancer.
N Engl J Med. 2020 Jan 2;382(1):60-72. doi: 10.1056/NEJMra1715715.
4
TRIM67 Activates p53 to Suppress Colorectal Cancer Initiation and Progression.
Cancer Res. 2019 Aug 15;79(16):4086-4098. doi: 10.1158/0008-5472.CAN-18-3614. Epub 2019 Jun 25.
5
An update: emerging drugs to treat squamous cell carcinomas of the head and neck.
Expert Opin Emerg Drugs. 2018 Dec;23(4):283-299. doi: 10.1080/14728214.2018.1543400. Epub 2018 Nov 16.
6
Dual Targeting of Aurora Kinases with AMG 900 Exhibits Potent Preclinical Activity Against Acute Myeloid Leukemia with Distinct Post-Mitotic Outcomes.
Mol Cancer Ther. 2018 Dec;17(12):2575-2585. doi: 10.1158/1535-7163.MCT-18-0186. Epub 2018 Sep 28.
7
Tumor Mutational Burden and Response Rate to PD-1 Inhibition.
N Engl J Med. 2017 Dec 21;377(25):2500-2501. doi: 10.1056/NEJMc1713444.
8
Recent omics technologies and their emerging applications for personalised medicine.
IET Syst Biol. 2017 Jun;11(3):87-98. doi: 10.1049/iet-syb.2016.0016.
9
FOXM1 recruits nuclear Aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells.
Oncogene. 2017 Jun 15;36(24):3428-3440. doi: 10.1038/onc.2016.490. Epub 2017 Jan 23.
10
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
J Clin Oncol. 2016 Nov 10;34(32):3838-3845. doi: 10.1200/JCO.2016.68.1478. Epub 2016 Sep 30.
Zotero 插件